Notices
27 February 2004
Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice
Marina Tinel, Alain Berson, Nathalie Vadrot, Véronique Descatoire, Alain Grodet, Gérard Feldmann, Jean Paul Thénot, Dominique Pessayre – 27 February 2004 – The hepatotoxicity of several drugs is increased by mild viral infections. During such infections, death receptor ligands are expressed at low levels, and most parenchymal cells survive. We tested the hypothesis that subliminal death receptor stimulation may aggravate the hepatotoxicity of drugs, which are transformed by cytochrome P‐450 cytochrome P‐450 into glutathione‐depleting reactive metabolites.
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C
Sophie Le Calvez, Dominique Thabut, Djamila Messous, Mona Munteanu, Vlad Ratziu, Francoise Imbert‐Bismut, Thierry Poynard – 27 February 2004
News from Spain
Juan Rodés – 27 February 2004
Expression of Granzyme B in viral hepatitis in patients with ALPS
Nicolas André, Bertrand Roquelaure, Isabelle Thuret, Marianne Ziol, Frédéric Rieux‐Laucat, Françoise Le Deist – 27 February 2004
Chronic hepatitis B: Update of recommendations
Anna S.F. Lok, Brian J. McMahon – 27 February 2004
Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials
Stephen H. Caldwell, Charissa Chang, B. Gail Macik – 27 February 2004 – The management of coagulopathy in patients with acute and chronic liver disease has undergone little change in many years despite advances in our understanding of the pathogenesis of this problem. In general, deficiency of clotting factors as a result of poor hepatic synthetic function accounts for most of the coagulopathy.
Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion
Anna Serafín, Joan Roselló‐Catafau, Neus Prats, Emilio Gelpí, Joan Rodés, Carmen Peralta – 27 February 2004 – The present study evaluates the effect of ischemic preconditioning on interleukin‐1 (IL‐1) and interleukin‐10 (IL‐10) generation following hepatic ischemia/reperfusion (I/R) in normal and steatotic livers as well as the role of nitric oxide (NO) in this process. Increased IL‐1β and IL‐10 levels were observed in normal livers after I/R. Steatotic livers showed higher IL‐1β levels than normal livers, and IL‐10 at control levels.
Nontumoral dermatologic problems after liver transplantation
Edmond Schmied, Jean‐François Dufour, Sylvie Euvrard – 26 February 2004 – The skin, easily accessible for medical examination, is affected in many ways by liver transplantation. Mucocutaneous manifestations of advanced liver disease and dermatologic conditions associated with specific hepatic diagnoses generally improve after liver transplantation. Vasculitic lesions due to cryoglobulinemia associated with hepatitis C, and photosensitivity due to porphyria are occasional exceptions. Dermatologic diseases complicating the posttransplantation course can be challenging.
New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection
Mandana Khalili, Jessica Watson Lim, Nathan Bass, Nancy L. Ascher, John P. Roberts, Norah A. Terrault – 26 February 2004 – Epidemiological studies suggest diabetes mellitus (DM) may be an extrahepatic manifestation of chronic hepatitis C virus (HCV) infection. Since diabetes and HCV are common in liver transplant recipients, we sought to examine the unique contribution of HCV infection to risk of de novo diabetes posttransplantation. Using a cohort of 555 liver transplant recipients (median age 49 years, 54% males, 82% Caucasian) without preexisting diabetes from 3 U.S.